FK506-binding protein 1A–mechanistic target of rapamycin complex 1 (FKBP12–mTORC1)

FKBP12–mTORC1 refers to the functional protein complex formed when the 12 kDa FK506-binding protein (FKBP12) interacts with the mechanistic target of rapamycin complex 1 (mTORC1). This interaction is typically mediated by rapamycin or its analogs (rapalogs), which bridge the two proteins to form a stable ternary complex. mTORC1 is a master regulator of cellular metabolism and growth, integrating signals from growth factors, nutrients, and energy status to promote anabolic processes like protein synthesis while inhibiting catabolic processes like autophagy (UniProt P42345, P62942). Formation of the FKBP12–mTORC1 complex allosterically inhibits the kinase activity of mTOR, specifically targeting the mTORC1 assembly rather than mTORC2. In clinical practice, targeting this complex is a cornerstone of immunosuppressive therapy to prevent organ transplant rejection and is widely used in oncology to treat various malignancies, including renal cell carcinoma and breast cancer. It also plays a critical role in treating genetic disorders such as tuberous sclerosis complex (TSC), where mTORC1 is constitutively overactive. Despite its therapeutic efficacy, chronic inhibition of the FKBP12–mTORC1 pathway can lead to metabolic side effects such as dyslipidemia and insulin resistance, as well as increased susceptibility to infections due to its potent immunosuppressive properties (StatPearls: mTOR Inhibitors).

Other names

FKBP12-mTORC1 complexFKBP1A-mTORC1Rapamycin-FKBP12-mTOR complexFK506-binding protein 12–mTORC1

Rapalogs act as molecular glues that bind to the prolyl isomerase FKBP12; this binary complex then binds to the FKBP-rapamycin binding (FRB) domain of mTOR within the mTORC1 complex, resulting in allosteric inhibition of its kinase activity (PMID: 12150925, 22566071).